You just read:

Impel NeuroPharma Announces FDA Clearance of IND for Pivotal Phase 3 Study of INP104 for Acute Treatment of Migraine

News provided by

Impel NeuroPharma, Inc.

Jun 22, 2018, 08:15 ET